Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Capital Leases: 2011-2020

Historic Capital Leases for Adma Biologics (ADMA) over the last 6 years, with Dec 2020 value amounting to $4.3 million.

  • Adma Biologics' Capital Leases rose 250.48% to $6.4 million in Q1 2021 from the same period last year, while for Mar 2021 it was $6.4 million, marking a year-over-year increase of 250.48%. This contributed to the annual value of $4.3 million for FY2020, which is N/A change from last year.
  • Per Adma Biologics' latest filing, its Capital Leases stood at $4.3 million for FY2020, which was up 3,539.70% from $119,080 recorded in FY2018.
  • Over the past 5 years, Adma Biologics' Capital Leases peaked at $4.3 million during FY2020, and registered a low of $19,697 during FY2016.
  • In the last 2 years, Adma Biologics' Capital Leases had a median value of $2.2 million in 2018 and averaged $2.2 million.
  • Data for Adma Biologics' Capital Leases shows a maximum YoY plummeted of 45.67% (in 2016) over the last 5 years.
  • Adma Biologics' Capital Leases (Yearly) stood at $19,697 in 2016, then followed by $119,080 in 2018, then followed by $4.3 million in 2020.